{"id":"W4379328967","doi":"10.1200/jco.2023.41.16_suppl.tps1115","title":"HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Internal medicine; Metastatic breast cancer; Capecitabine; Oncology; Trastuzumab; Neratinib; Taxane; Progression-free survival; Breast cancer; Cancer; Colorectal cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00175468,0.001854634,0.002204097,0.0007090376,0.0004794681,0.001306682,0.001586345,0.001994994,0.008059407],"category_scores_gemma":[0.0009783361,0.0008430961,0.001999688,0.0005199802,0.0009846579,0.001201237,0.0004042739,0.003718577,0.001748298],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001159206,"about_ca_system_score_gemma":0.001950383,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002157354,"about_ca_topic_score_gemma":0.006393405,"domain_scores_codex":[0.9996074,0.0001746596,0.00001712774,0.00006398706,0.00004347957,0.00009333514],"domain_scores_gemma":[0.9994012,0.00007519963,0.0001191938,0.00003677846,0.0000388204,0.0003287794],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8740441,0.06210485,0.001197398,0.001007592,0.001362896,0.0001001294,0.0001415865,0.001032219,0.01311482,0.0002305862,0.003717647,0.04194629],"study_design_scores_gemma":[0.7676982,0.2251596,0.003000208,0.00004153602,0.0004065307,0.0001022373,0.00003953795,0.0006375965,0.001148094,0.0001371852,0.001605394,0.00002388612],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9765111,0.005715864,0.0008325751,0.0009123648,0.0005003382,0.007864511,0.003402634,0.0004219418,0.003838707],"genre_scores_gemma":[0.9719702,0.004574683,0.001997502,0.002038133,0.0003258088,0.008210091,0.004028976,0.00006667955,0.006787855],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008059407,"threshold_uncertainty_score":0.02696145,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1344986167028801,"score_gpt":0.5150052673203316,"score_spread":0.3805066506174515,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}